Phase II Study of Doxercalciferol for the Treatment of Myelodysplastic Syndromes
- Determine the response rate of patients with myelodysplastic syndromes or chronic
myelomonocytic leukemia treated with doxercalciferol.
- Determine the toxicity profile of this drug in these patients.
- Determine the time to progression and overall survival of patients treated with this
OUTLINE: Patients receive oral doxercalciferol daily for 12 weeks. Treatment continues in
the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: Approximately 41 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Mark B. Juckett, MD
University of Wisconsin, Madison
United States: Federal Government
|University of Wisconsin Comprehensive Cancer Center||Madison, Wisconsin 53792|